Pfizer Inc is ceasing the clinical development of sumanirole, a compound under investigation for the treatment of Parkinson's disease and Restless Leg Syndrome.
The decision is based on results of recent studies that failed to sufficiently distinguish sumanirole from currently available therapies. While the compound may still prove effective in these conditions, it did not meet Pfizer's criteria for continued development, company said in a release.